269 related articles for article (PubMed ID: 23222490)
1. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
4. The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas.
Xu X; Jin H; Liu Y; Liu L; Wu Q; Guo Y; Yu L; Liu Z; Zhang T; Zhang X; Dong X; Quan C
Diagn Pathol; 2012 Mar; 7():33. PubMed ID: 22455563
[TBL] [Abstract][Full Text] [Related]
5. Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis.
Taliano RJ; Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
Hum Pathol; 2013 Dec; 44(12):2743-50. PubMed ID: 24262018
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
[TBL] [Abstract][Full Text] [Related]
7. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
9. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.
Blanchard AA; Skliris GP; Watson PH; Murphy LC; Penner C; Tomes L; Young TL; Leygue E; Myal Y
Virchows Arch; 2009 Jun; 454(6):647-56. PubMed ID: 19387682
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
11. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer.
Yakirevich E; Samkari A; Holloway MP; Lu S; Singh K; Yu J; Fenton MA; Altura RA
Hum Pathol; 2012 Jun; 43(6):865-73. PubMed ID: 22055399
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
13. Claudin 1 expression in basal-like breast cancer is related to patient age.
Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
[TBL] [Abstract][Full Text] [Related]
14. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
Tamimi RM; Baer HJ; Marotti J; Galan M; Galaburda L; Fu Y; Deitz AC; Connolly JL; Schnitt SJ; Colditz GA; Collins LC
Breast Cancer Res; 2008; 10(4):R67. PubMed ID: 18681955
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
17. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
19. [Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
Li MP; Ren LF; Cai HG; Yang HY; Lu B; Zhang P; Bao L
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):182-5. PubMed ID: 23769438
[TBL] [Abstract][Full Text] [Related]
20. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
